FEATURED

Supreme Court Ruling, Arrival of Biosimilars

The Supreme Court's ruling in the Amgen v Sandoz case may hasten the arrival of lower-cost biosimilar versions of biologics in the clinic, potentially saving billions of dollars in health care spending.

Q&A With Filippo Montemurro, MD

Cancer Therapy Advisor asked Filippo Montemurro, MD, to place recent findings in context with respect to when T-DM1 might be best indicated.

Vaccines Targeting Multiple Myeloma Offer Promise

Vaccines targeting multiple myeloma antigens offer a promising therapeutic approach by helping the immune system to fight off cancer cells.

Fact Sheet: Dietary Nutrients, Oncogenic HPV

Additional large, well-designed studies are needed to clarify the roles of dietary nutrients in HPV infection persistence and cancer risk.

Abemaciclib for Advanced Breast Cancer

Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.

ASCO: Future Treatment Modalities in Sarcoma

Targeted and immunotherapeutic approaches are poised to change how sarcoma will be treated in the future. Trials are being used to match tumors with appropriate treatment choices.

Metastatic Breast Cancer: Overcoming Drug Resistance

The management of metastatic breast cancer resistant or refractory to hormonal treatments, while still challenging, is rapidly improving.

Aldoxorubicin: A Way Forward for STS?

Although aldoxorubicin did not improve OS, the available evidence suggests that it is nevertheless superior to doxorubicin — particularly among patients with liposarcoma and leiomyosarcoma.

Don Dizon, MD, on ASCO 2017

The American Society of Clinical Oncology (ASCO) Annual Meeting wrapped up early in June, and what a meeting it was.

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

In ER+, early-stage breast cancer

Individualizing treatment with extended adjuvant endocrine therapy

For the treatment of metastatic non-small

Biomarker testing for epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations is important when considering a first-line therapy

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

In ER+, early-stage breast cancer

Experts discuss risk vs benefit of extended adjuvant endocrine therapy

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

Latest Features

Supreme Court Ruling Should Hasten Arrival of Biosimilars, But Uncertainties Remain

Supreme Court Ruling Should Hasten Arrival of Biosimilars, But Uncertainties Remain

The Supreme Court's ruling in the Amgen v Sandoz case may hasten the arrival of lower-cost biosimilar versions of biologics in the clinic, potentially saving billions of dollars in health care spending.

Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine

Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine

Cancer Therapy Advisor asked Filippo Montemurro, MD, to place recent findings in context with respect to when T-DM1 might be best indicated.

Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach

Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach

Vaccines targeting multiple myeloma antigens offer a promising therapeutic approach by helping the immune system to fight off cancer cells.

In Focus: Abemaciclib for Advanced Breast Cancer

In Focus: Abemaciclib for Advanced Breast Cancer

Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.

Future Treatment Modalities in Sarcoma: Insights From ASCO 2017

Future Treatment Modalities in Sarcoma: Insights From ASCO 2017

Targeted and immunotherapeutic approaches are poised to change how sarcoma will be treated in the future. Trials are being used to match tumors with appropriate treatment choices.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters